Document is current
Any future updates will be listed below
-
Authors
Karp, Natasha A.
Berdoy, Manuel
Gray, Kelly
Hunt, Lilian https://orcid.org/0000-0002-0319-7764
Jennings, Maggy
Kerton, Angela https://orcid.org/0000-0003-1427-6318
Leach, Matt
Tremoleda, Jordi L. https://orcid.org/0000-0002-8846-9043
Gledhill, Jon
Pearl, Esther J. https://orcid.org/0000-0001-6510-0959
Percie du Sert, Nathalie https://orcid.org/0000-0002-9478-0540
Phillips, Benjamin
Reynolds, Penny S.
Ryder, Kathy https://orcid.org/0000-0003-2126-1296
Stanford, S. Clare
Wells, Sara https://orcid.org/0000-0002-0572-0600
Whitfield, Lucy
- License Information
-
More Information
Article History
Received: 14 March 2024
Accepted: 26 March 2025
First Online: 22 April 2025
Competing interests
: The authors declare the following competing interests: B.P., K.G. and N.A.K. have shareholdings in AstraZeneca. E.J.P. and N.P.d.S. are NC3Rs staff; whose role includes promoting the ARRIVE guidelines and the Experimental Design Assistant (EDA). N.A.K. and S.C.S. are members of the expert group who advise development of the EDA, S.C.S. is also the Chair of the EDA Project Management Board. The remaining authors declare no competing interests.
